Etoposide-Loaded PLGA and PCL Nanoparticles I: Preparation and Effect of Formulation Variables

Drug Delivery

Volumn 15, Issue 5, 2008, Pages 267-275

  Snehalatha, Movva ^a   Venugopal, Kolachina ^a   Saha, Ranendra N ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

Etoposide; Nanoparticles; Nanoprecipitation

Indexed keywords

EID: 84922520498     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.1080/10717540802174662     Document Type: Article

References (25)

1. I. Bala, S. Hariharan, and M. N. Kumar. (2004). PLGA nanoparticles in drug delivery: the state of the art. Crit. Rev. Ther. Drug Carrier. Syst. 21: 387 – 422.
2. I. Brigger, C. Dubernet, and P. Couvreur. (2002). Nanoparticles in cancer therapy and diagnosis. Adv. Drug Del. Rev. 54: 631 – 651.
3. A. Budhian, S. J. Siegel, and K. I. Winey. (2005). Production of haloperidol-loaded PLGA nanoparticles for extended controlled drug release of haloperidol. J. Microencapsul. 22: 773 – 785.
4. A. Budhian, S. J. Siegel, and K. I. Winey. (2007). Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content. Int. J. Pharm. 336: 367 – 375.
5. M. Chorny, I. Fishbein, H. D. Danenberg, and G. Golomb. (2002). Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics. J. Control. Release 83: 389 – 400.
6. M. D. Coffin, and J. W. McGinity. (1992). Biodegradable pseudolatexes: the chemical stability of poly (D, L-lactide) and poly (ε -caprolactone) nanoparticles in aqueous media. Pharm. Res. 9: 200 – 205.
7. M. S. Espuelas, P. Legrand, J. M. Irache, C. Gamazo, A. M. Orecchioni, J. P. Devissaguet, and P. Ygartua. (1997). Poly (ε -caprolacton) nanospheres as an alternative way to reduce amphotericin B toxicity. Int. J. Pharm. 158: 19 – 27.
8. S.-S. Feng, and G. Huang. (2001). Effects of emulsifiers on the controlled release of paclitaxel (Taxol®) from nanospheres of biodegradable polymers. J. Control. Release 71: 53 – 69.
9. H. Fessi, F. Puisieux, J. P. Devissaguet, N. Ammoury, and S. Benita. (1989). Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int. J. Pharm. 55: R1 – R4.
10. C. Gomez-Gaete, N. Tsapis, M. Besnard, A. Bochot, and E. Fattal. (2007). Encapsulation of dexamethasone into biodegradable polymeric nanoparticles. Int. J. Pharm. 331: 153 – 159.
11. W. He, S. W. Horn, and M. D. Hussain. (2007). Improved bioavailability of orally administered mifepristone from PLGA nanoparticles. Int. J. Pharm. 334: 173 – 178.
12. M. N. Kumar, and N. Kumar. (2001). Polymeric controlled drug-delivery systems: perspective issues and opportunities. Drug Dev. Ind. Pharm. 27: 1 – 30.
13. H.-Y. Kwon, J.-Y. Lee, S.-W. Choi, Y. Jang, and J.-H. Kim. (2001). Preparation of PLGA nanoparticles containing estrogen by emulsification-diffusion method. Colloids Surf. A: Physicochem. Eng. Aspects 182: 123 – 130.
14. A. Lamprecht, N. Ubrich, M. Hombreiro Perez, C. M. Lehr, M. Hoffman, and P. Maincent. (2000). Influences of process parameters on nanoparticle preparation performed by a double emulsion pressure homogenization technique. Int. J. Pharm. 196: 177 – 182.
15. D. Lemoine, C. Francois, F. Kedzierewicz, V. Preat, M. Hoffman, and P. Maincent. (1996). Stability study of nanoparticles of poly (ε -caprolactone), poly (D, L-lactide) and poly(D, L-lactide-co-glycolide). Biomaterials 17: 2191 – 2197.
16. J. C. Leroux, E. Allemann, E. Doelker, and R. Gurny. (1995). New approach for the preparation of nanoparticles by an emulsification diffusion method. Eur. J. Pharm. Biopharm. 41: 14 – 18.
17. M. Y. Levy, and S. Benita. (1990). Drug release from submicronized o/w emulsion: a new in vitro kinetic evaluation model. Int. J. Pharm. 66: 29 – 37.
18. H. Murakami, M. Kobayashi, H. Takeuchi, and Y. Kawashima. (1999). Preparation of poly (dl-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method. Int. J. Pharm. 187: 143 – 152.
19. P. J. O'Dwyer, B. Leyland-Jones, M. T. Alonso, S. Marsoni, and R. E. Wittes. (1985). Etoposide (VP-16–213). Current status of an active anticancer drug. N. Engl. J. Med. 312: 692 – 700.
20. Y. Ogawa, M. Yamamoto, H. Okada, T. Yashiki, and T. Shimamoto. (1988). A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid. Chem. Pharm. Bull. 36: 1095 – 1103.
21. L. Peltonen, P. Koistinen, M. Karjalainen, A. Hakkinen, and J. Hirvonen. (2002). The effect of cosolvents on the formulation of nanoparticles from low-molecular-weight poly(l)lactide. AAPS Pharm. Sci. Tech. 3: E32.
22. D. Quintanar-Guerrero, H. Fessi, E. Allemann, and E. Doelker. (1996). Influence of stabilizing agents and preparative variables on the formation of poly (d,l-lactic acid) nanoparticles by an emulsification-diffusion technique. Int. J. Pharm. 143: 133 – 141.
23. J. C. Shah, J. R. Chen, and D. Chow. (1989). Preformulation study of etoposide: identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide. Pharm. Res. 6: 408 – 412.
24. K. S. Soppimath, T. M. Aminabhavi, A. R. Kulkarni, and W. E. Rudzinski. (2001). Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 70: 1 – 20.
25. K. Yamaoka, T. Nakagawa, and T. Uno. (1978). Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6: 165 – 175.